Phase II study of bisantrene administered by continuous 72-hour infusion for advanced pancreatic adenocarcinoma

MLA

Michael J. O’Connell, et al. “Phase II Study of Bisantrene Administered by Continuous 72-Hour Infusion for Advanced Pancreatic Adenocarcinoma.” Medical and Pediatric Oncology, vol. 16, Jan. 1988, pp. 269–70. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1b862ab4dfe8a638d32f7513d9e9cb1b&authtype=sso&custid=ns315887.

APA

Michael J. O’Connell, Larry K. Kvols, Robert F. Marschke, John A. Laurie, Stephen A. Cullinan, James A. Mailliard, & Loren K. Tschetter. (1988). Phase II study of bisantrene administered by continuous 72-hour infusion for advanced pancreatic adenocarcinoma. Medical and Pediatric Oncology, 16, 269–270.

Chicago

Michael J. O’Connell, Larry K. Kvols, Robert F. Marschke, John A. Laurie, Stephen A. Cullinan, James A. Mailliard, and Loren K. Tschetter. 1988. “Phase II Study of Bisantrene Administered by Continuous 72-Hour Infusion for Advanced Pancreatic Adenocarcinoma.” Medical and Pediatric Oncology 16 (January): 269–70. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1b862ab4dfe8a638d32f7513d9e9cb1b&authtype=sso&custid=ns315887.